Flex Pharma Inc (NASDAQ:FLKS) has been given an average rating of “Hold” by the six analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $9.50.
A number of research firms have issued reports on FLKS. ValuEngine upgraded Flex Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research upgraded Flex Pharma from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Friday, December 1st. Cantor Fitzgerald reiterated a “hold” rating and issued a $10.00 target price on shares of Flex Pharma in a research report on Wednesday, January 17th. Ladenburg Thalmann Financial Services began coverage on Flex Pharma in a research report on Thursday, January 25th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Roth Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Flex Pharma in a research report on Wednesday, January 3rd.
Flex Pharma (NASDAQ:FLKS) opened at $7.36 on Friday. Flex Pharma has a 12-month low of $2.68 and a 12-month high of $8.98. The stock has a market capitalization of $103.70, a PE ratio of -3.68 and a beta of 3.33.
Flex Pharma (NASDAQ:FLKS) last released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.10. Flex Pharma had a negative return on equity of 85.02% and a negative net margin of 2,698.59%. The firm had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.36 million. equities analysts expect that Flex Pharma will post -1.88 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in FLKS. Sphera Funds Management LTD. acquired a new position in shares of Flex Pharma in the third quarter worth approximately $2,341,000. Ameriprise Financial Inc. lifted its stake in shares of Flex Pharma by 10.0% in the third quarter. Ameriprise Financial Inc. now owns 720,524 shares of the biotechnology company’s stock worth $2,457,000 after acquiring an additional 65,699 shares during the period. Granite Point Capital Management L.P. lifted its stake in shares of Flex Pharma by 80.8% in the fourth quarter. Granite Point Capital Management L.P. now owns 71,520 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 31,961 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Flex Pharma by 67.1% in the fourth quarter. Renaissance Technologies LLC now owns 89,900 shares of the biotechnology company’s stock worth $314,000 after acquiring an additional 36,100 shares during the period. Institutional investors own 28.96% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Flex Pharma Inc (FLKS) Receives Average Recommendation of “Hold” from Brokerages” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/flex-pharma-inc-flks-receives-average-recommendation-of-hold-from-brokerages.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.